araag2/HINT huggingface dataset:
Clinical trial NCT02763579 (phase 3, status: active, not recruiting)
Conditions: small cell lung carcinoma
ICD codes: D02.20, D02.21, D02.22
Drugs: atezolizumab (mpdl3280a), an engineered anti-pd-l1 antibody, carboplatin, etoposide, placebo
SMILES: CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1, N[C@@H](CCCNC(N)=N)C(O)=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration
             Lung Study Group [VALG] staging system)

          -  No prior systemic treatment for ES-SCLC

          -  Eastern Cooperative Oncology Group performance status of 0 or 1

          -  Measurable disease, as defined by RECIST v1.1

          -  Adequate hematologic and end organ function

          -  Treatment-free for at least 6 months since last chemo/radiotherapy, among those
             treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC

        Exclusion Criteria:

          -  Active or untreated central nervous system (CNS) metastases as determined by computed
             tomography (CT) or magnetic resonance imaging (MRI) evaluation

          -  Malignancies other than SCLC within 5 years prior to randomization, with the exception
             of those with a negligible risk of metastasis or death treated with expected curative
             outcome

          -  Pregnant or lactating women

          -  History of autoimmune disease

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
             chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is
             permitted.

          -  Positive test result for human immunodeficiency virus (HIV)

          -  Active hepatitis B or hepatitis C

          -  Severe infections at the time of randomization

          -  Significant cardiovascular disease

          -  Prior treatment with cluster of differentiation (CD) 137 agonists or immune checkpoint
             blockade therapies, anti-programmed death-1 (PD-1), and anti-PD-L1 therapeutic
             antibody

          -  History of severe (or known) hypersensitivity to chimeric or humanized antibodies or
             fusion proteins or any component of atezolizumab formulation.
Clinical trial NCT02766777 (phase 3, status: completed)
Conditions: constipation - functional
ICD codes: K59.00, K59.09, K59.01, K59.02, K59.03, K59.04, K58.1
Drugs: lubiprostone
SMILES: [H][C@@]12CC(=O)[C@H](CCCCCCC(O)=O)[C@@]1([H])CC[C@@](O)(O2)C(F)(F)CCCC
Eligibility criteria:

        Inclusion Criteria:

          -  Medically-confirmed diagnosis of Functional Constipation per Rome III Diagnostic
             Criteria for Childhood Functional Constipation

          -  At least 6 years of age but less than 18 years of age at the time of randomisation

          -  Only stable dose of selective serotonin re-uptake inhibitors (SSRIs),
             serotonin-specific reuptake inhibitor (SNRIs), or monoamine oxidase inhibitors (MAO)
             inhibitors are allowed if participant is taking antidepressants

        Exclusion Criteria:

          -  Any gastrointestinal (GI) condition, other than constipation, affecting GI motility or
             defecation

          -  Untreated faecal impaction at the time of screening

          -  Medical/surgical condition that might interfere with the absorption, distribution,
             metabolism, or excretion of the study medication
Clinical trial NCT02773368 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec/liraglutide, insulin glargine
SMILES: CN(C)C(=N)NC(N)=N, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria: - Male or female, age at least 18 years at the time of signing informed
        consent - Subjects diagnosed (clinically) with type 2 diabetes mellitus - HbA1c 7.0-11.0%
        [53-97 mmol/mol] (both inclusive) by central laboratory analysis - Body mass index (BMI)
        equal to or above 20 kg/m^2 and below 40 kg/m^2 - Insulin naïve subjects; however short
        term insulin treatment for a maximum of 14 days prior to the day of screening is allowed,
        as well as prior insulin treatment for gestational diabetes - A stable daily dose for at
        least 90 days prior to the day of screening of any SGLT2i in monotherapy or in combination
        with metformin ± DPP4i ± pioglitazone. Use of pioglitazone is not allowed in subjects
        treated with dapagliflozin Exclusion Criteria: - Receipt of any investigational medicinal
        product within 90 days prior to screening - Use of any OADs (other than SGLT2i in
        monotherapy or in combination with metformin or DPP4i or pioglitazone as described in the
        inclusion criteria) within 90 days prior to the day of screening - Use of glucagon-like
        peptide-1 (GLP-1) receptor agonist (e.g., exenatide or liraglutide) within 90 days prior to
        the day of screening - Acute decompensation of glycaemic control requiring immediate
        intensification of treatment to prevent severe metabolic dysregulation (e.g., diabetes
        ketoacidosis) in the previous 90 days prior to the day of the screening - Subjects
        presently classified as being in NYHA (New York Heart Association) Class III or IV1 - Renal
        impairment estimated Glomerular Filtration Rate 60 mL/min/1.73 m2 as per CKD-EPI (Chronic
        Kidney Disease Epidemiology Collaboration) - Impaired liver function, defined as ALT
        (alanine aminotransferase) equal to or above 2.5 times upper normal limit at screening -
        Known or suspected hypersensitivity to trial product(s) or related products
Clinical trial NCT02774187 (phase 3, status: completed)
Conditions: hepatocellular carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: sorafenib, folfox protocol
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  The diagnosis of HCC was based on the diagnostic criteria for HCC used by the European
             Association for the Study of the Liver (EASL)

          -  Patients must have at least one tumor lesion that can be accurately measured according
             to EASL criteria.

          -  portal vein tumor thrumbus confirmed in two image techniques

          -  Eastern Cooperative Oncology Group performance status of 0 to 2

          -  with no previous treatment

          -  No Cirrhosis or cirrhotic status of Child-Pugh class A only

          -  Not amendable to surgical resection ,local ablative therapy and any other cured
             treatment.

          -  The following laboratory parameters:

               -  Platelet count ≥ 75,000/µL

               -  Hemoglobin ≥ 8.5 g/dL

               -  Total bilirubin ≤ 30mmol/L

               -  Serum albumin ≥ 30 g/L

               -  ASL and AST ≤ 5 x upper limit of normal

               -  Serum creatinine ≤ 1.5 x upper limit of normal

               -  INR ≤ 1.5 or PT/APTT within normal limits

               -  Absolute neutrophil count (ANC) >1,500/mm3

          -  Ability to understand the protocol and to agree to and sign a written informed consent
             document

        Exclusion Criteria:

          -  Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or
             hepatic encephalopathy

          -  Known history of HIV

          -  History of organ allograft

          -  Known or suspected allergy to the investigational agents or any agent given in
             association with this trial.

          -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy

          -  Evidence of bleeding diathesis.

          -  Patients with clinically significant gastrointestinal bleeding within 30 days prior to
             study entry.

          -  Known central nervous system tumors including metastatic brain disease
Clinical trial NCT02775006 (phase 3, status: terminated)
Conditions: carcinoma, non-small cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: docetaxel, erlotinib
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Reason stopped: 
    accrual to slow, target not achievable
  
Eligibility criteria:

        Inclusion Criteria:

          1. Histologically or cytologically confirmed EGFR wild type, ALK negative, non-squamous
             cell carcinoma, locally advanced and metastatic disease stage IIIB and IV. Evidence of
             disease progression after one cytotoxic treatment platinum containing regimen.
             Immunotherapy pretreatment is allowed

          2. Complete recovery from prior chemotherapy side effects to < Grade 2.

          3. At least one unidimensionally measurable lesion meeting RECIST criteria.

          4. ECOG PS 0-1.

          5. Age ≥ 18 years.

          6. Adequate organ function, including:

               -  Adequate bone marrow reserve: ANC > 1.5 x 109/L, platelets ≥ 100 x 109/L.

               -  Hepatic: bilirubin ≤1.5 x ULN (upper limit normal), AP, ALT, AST ≤ 1.5 x ULN. AP,
                  ALT, and AST ≤5 x ULN is acceptable if the liver has tumor involvement.

               -  Renal: calculated creatinine clearance ≥ 40 ml/min based on the Cockcroft-Gault
                  formula.

          7. Male and female patients with reproductive potential must use an approved
             contraceptive method, if appropriate. Female patients with childbearing potential must
             have a negative serum pregnancy test within 7 days prior to study enrollment.

          8. Signed informed consent.

          9. Patient compliance and geographical proximity that allow adequate follow up.

         10. Patients who have undergone cranial irradiation for brain metastases more than 4 weeks
             before inclusion in our protocol, provided that they are clinically fit to undergo
             second line treatment

        Exclusion Criteria:

          1. Pregnant or lactating women.

          2. Patients with medical risks because of non-malignant disease as well as those with
             active uncontrolled infection.

          3. Documented brain metastases unless the patient has completed local therapy for central
             nervous system metastases at least 4 weeks before enrollment and has been off
             corticosteroids for at least two weeks before enrollment. Prophylactic irradiation at
             least 4 weeks prior to enrollment is accepted.

          4. Maintenance treatment with erlotinib or other TKI (Tyrosine Kinase Inhibitor), or
             docetaxel. Maintenance treatment with pemetrexed is allowed. Previous treatment with
             an EGFR-TKI or docetaxel within 6 months prior to enrollment.

          5. Inability or unwillingness to take dexamethasone.

          6. Concomitant treatment with any other experimental drug under investigation.

          7. Patients experiencing disease progression within 2 months after the start of platinum
             based chemotherapy
Clinical trial NCT02777229 (phase 3, status: completed)
Conditions: hiv-1 infection
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: dolutegravir 50 mg, tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg, efavirenz 200 mg
SMILES: [H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N1[C@H](C)CCO2, C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O, FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1
Eligibility criteria:

        Inclusion Criteria:

          -  HIV-1 infected

          -  Age ≥ 18 years

          -  Abtiretroviral-naïve, including above 7 days of cumulative prior antiretroviral
             therapy at any time prior to study entry.

          -  For women of childbearing potential: acceptance to use effective contraceptive methods

          -  Provision of written informed consent

        Exclusion Criteria:

          -  Infection with HIV-1 group O, N, P

          -  Infection or co-infection with HIV-2

          -  Absolute neutrophil count (ANC) < 500 cells/mm3

          -  Hemoglobin < 7.0 g/dL

          -  Platelet count < 50,000 cells/mm3

          -  AST and/or ALT > 5 x Upper Limit of Normal (ULN)

          -  Calculated creatinine clearance < 50 mL/min

          -  Active opportunistic or severe disease not under adequate control

          -  For women of childbearing age : Pregnancy/breastfeeding

          -  History or presence of allergy and/or contraindications to the trial drugs or their
             components

          -  Severe psychiatric illness

          -  Severe hepatic failure Patients co-infected with tuberculosis (TB), receiving a TB
             treatment and with stable clinical condition will not be excluded.
Clinical trial NCT02779959 (phase 3, status: unknown status)
Conditions: migraine disorders
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: prochlorperazine
SMILES: CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients between 18-65 years of age evaluated in the emergency department at
             Harbor-UCLA with migraine headache as defined by the Headache Classification Committee
             of the International Headache Society. (Patients must have had at least one prior
             similar headache, with or without nausea, vomiting, aura, photophobia, or
             phonophobia).

          -  Only subjects able to consent to treatment will be included.

        Exclusion Criteria:

        Patients with the following conditions:

          -  pregnancy

          -  breastfeeding

          -  fever greater or equal to 100.4 degrees

          -  diastolic blood pressure of 105 or higher

          -  altered mental status

          -  meningeal signs

          -  suspicion for intracranial process requiring further investigation

          -  known allergy to prochlorperazine

          -  the use of ergotamines, antiemetics, antipsychotics or sedatives in the previous 24
             hours of study entry.
Clinical trial NCT02785900 (phase 3, status: terminated)
Conditions: acute myeloid leukemia
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: 33a, placebo, azacitidine, decitabine
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, CN(C)\N=N\C1=C(N=CN1)C(N)=O
Reason stopped: 
    due to safety; specifically a higher rate of deaths, including fatal infections, in the sgn33a
    arm versus the control arm
  
Eligibility criteria:

        Inclusion Criteria:

          -  Newly diagnosed, previously untreated, cytologically/histologically confirmed de novo
             or secondary AML according to World Health Organization (WHO) classification (except
             for acute promyelocytic leukemia (APL))

          -  Intermediate or adverse cytogenetic risk

          -  Eligible for therapy with either decitabine or azacitidine

          -  Acceptable hematologic and organ function

        Exclusion Criteria:

          -  AML associated with favorable risk karyotypes including inv(16), t(8;21), t(16;16), or
             t(15;17)

          -  Patients who are candidates for allogeneic stem cell transplant at the time of
             enrollment

          -  Patients with a history of one of the following myeloproliferative neoplasms:
             essential thrombocythemia, polycythemia vera, and primary myelofibrosis

          -  Received prior treatment with HMA or chemotherapy for antecedent myelodysplastic
             syndrome (MDS)
Clinical trial NCT02789033 (phase 3, status: completed)
Conditions: diabetic foot ulcers
ICD codes: H35.23, Z86.31, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: chitosan, isosorbide dinitrate, placebo
SMILES: [H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with diabetic foot ulcers in grade I and II of the classification of Wagner

          -  with leg arm index> 0.8 and

          -  without specific treatment for foot ulcers referred to the experimental and clinical

        Exclusion Criteria:

          -  Patients with another type of topical medication

          -  patients with diabetic foot ulcers in grade III and

          -  with leg arm index <0.8
Clinical trial NCT02792218 (phase 3, status: completed)
Conditions: relapsing multiple sclerosis
ICD codes: M94.1, A68.9, A68.0, A68.1, M35.6
Drugs: ofatumumab subcutaneous injection, teriflunomide-matching placebo capsules, teriflunomide capsule, matching placebo of ofatumumab subcutaneous injections
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  18 to 55 years of age

          -  Diagnosis of multiple sclerosis (MS)

          -  Relapsing MS: relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS)

          -  At least 1 relapse during the previous 1 year or 2 relapses during the previous 2
             years or a positive gadolinium-enhancing MRI scan in previous year

          -  Expanded disability status scale (EDSS) score of 0 to 5.5

        Exclusion Criteria:

          -  Primary progressive MS

          -  Disease duration of more than 10 years in patients with an EDSS score of 2 or less

          -  Patients with an active chronic disease of the immune system other than MS

          -  Patients at risk of developing or having reactivation of hepatitis

          -  Patients with active systemic infections or with neurological findings consistent with
             PML
Clinical trial NCT02792231 (phase 3, status: completed)
Conditions: relapsing multiple scelrosis
ICD codes: M94.1, A68.9, A68.0, A68.1, M35.6
Drugs: ofatumumab subcutaneous injection, teriflunomide-matching placebo capsules, teriflunomide capsule, matching placebo of ofatumumab subcutaneous injections
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  18 to 55 years of age

          -  Diagnosis of multiple sclerosis (MS)

          -  Relapsing MS: relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS)

          -  At least 1 relapse during the previous 1 year or 2 relapses during the previous 2
             years or a positive gadolinium-enhancing MRI scan in previous year

          -  Expanded disability status scale (EDSS) score of 0 to 5.5

        Exclusion Criteria:

          -  Primary progressive MS

          -  Disease duration of more than 10 years in patients with an EDSS score of 2 or less

          -  Patients with an active chronic disease of the immune system other than MS

          -  Patients at risk of developing or having reactivation of hepatitis

          -  Patients with active systemic infections or with neurological findings consistent with
             PML
Clinical trial NCT02792699 (phase 3, status: completed)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: abp 798, rituximab (us), rituximab (eu)
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Men or women ≥ 18 and ≤ 80 years old

          -  Subjects must be diagnosed with rheumatoid arthritis for at least 6 months before
             baseline

          -  Active RA defined as ≥ 6 swollen joints and ≥ 6 tender joints at screening and
             baseline and at least one of the following at screening:

               -  erythrocyte sedimentation rate (ESR) ≥ 28 mm/hr

               -  serum C-reactive protein (CRP) > 1.0 mg/dL

          -  Subjects must be taking methotrexate (MTX) for ≥ 12 consecutive weeks and on a stable
             dose of MTX 7.5 to 25 mg/week for ≥ 8 weeks prior to receiving the investigational
             product (IP), and be willing to remain on a stable dose throughout the study

          -  Subject has no known history of active tuberculosis

        Exclusion Criteria:

          -  Class IV RA, Felty's syndrome or history of prosthetic or native joint infection

          -  Major chronic inflammatory disease or connective tissue disease other than RA, with
             the exception of secondary Sjögren's syndrome

          -  Use of commercially available or investigational biologic therapies for RA as follows:

               -  anakinra, etanercept within 1 month prior to first dose of IP

               -  infliximab, abatacept, tocilizumab, golimumab, certolizumab within 3 months prior
                  to first dose of IP

               -  other experimental or commercially available biologic therapies for RA within 3
                  months or 5 half-lives (whichever is longer) prior to first dose of IP

          -  Previous receipt of rituximab or a biosimilar of rituximab

        Other Inclusion/Exclusion criteria may apply
Clinical trial NCT02793817 (phase 3, status: completed)
Conditions: post surgical ocular inflammation and pain
ICD codes: H01.9, H30.93, H05.00, H30.003, H30.013, H30.033, H30.103
Drugs: kpi-121 1% ophthalmic suspension dosed bid, vehicle of kpi-121 ophthalmic suspension dosed bid
SMILES: [H][C@@]12CC[C@](O)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

        Candidates for routine, uncomplicated cataract surgery

        In Investigator's opinion, potential postoperative Snellen Distance VA by pinhole method of
        at least 20/200 in study eye.

        Exclusion Criteria:

          -  Known hypersensitivity/contraindication to study product(s) or components.

          -  History of glaucoma, intraocular pressure (IOP) >21 mmHg at the screening or
             randomization visits, or being treated for glaucoma in either eye.

          -  Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in
             judgment of Investigator could confound study assessments or limit compliance;
             severe/serious systemic disease or uncontrolled medical condition that in judgment of
             Investigator could confound study assessments or limit compliance; or have been
             exposed to an investigational drug within the 30 days prior to screening or 18 days
             following surgery.

          -  In the opinion of Investigator or study coordinator, be unwilling or unable to comply
             with study protocol or unable to successfully instill eye drops.